Tuesday, September 1, 2009

POZEN Announces FDA Acceptance of NDA For VIMOVO

POZEN Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400).

the details can be read here.

No comments: